Arrowstreet Capital

Arrowstreet Capital’s Protalix BioTherapeutics PLX Stock Holding History

Arrowstreet Capital’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-23,353	Closed	-$85K	–	2465
2020 Q4	$85K	Sell	23,353 -22,500	-49%	-$80.6K	﹤0.01%	2231
2020 Q3	$177K	Buy	45,853 +11,200	+32%	+$40.5K	﹤0.01%	2219
2020 Q2	$131K	Buy	+34,653	New	+$118K	﹤0.01%	2204

Other funds holding PLX

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

Burrage Capital Management Boston, Massachusetts $99.7M AUM 66.05% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.37B AUM 63.08% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Susquehanna International Group

Susquehanna International Group Bala Cynwyd, Pennsylvania $77.3B AUM 36.07% 1-Year Est. Return

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return